Calvo Pier Luigi, Serpe Loredana, Brunati Andrea, Nonnato Antonello, Bongioanni Daniela, Olio Dominic Dell', Pinon Michele, Ferretti Carlo, Tandoi Francesco, Carbonaro Giulia, Salizzoni Mauro, Amoroso Antonio, Romagnoli Renato, Canaparo Roberto
Department of Pediatrics and Public Health Sciences, Division of Pediatric Gastroenterology, A.O.U. Città della Salute e della Scienza of Torino, University of Torino, Torino, Italy.
Department of Drug Science and Technology, University of Torino, Torino, Italy.
Br J Clin Pharmacol. 2017 Jun;83(6):1252-1262. doi: 10.1111/bcp.13219. Epub 2017 Jan 31.
The aim of the present study was to investigate the influence of the cytochrome P450 (CYP) 3A4/5 genotype in paediatric liver transplant recipients and donors, and the contribution of age and gender to tacrolimus disposition on the first day after transplantation.
The contribution of the CYP3A4/5 genotype in paediatric liver transplant recipients and donors to the tacrolimus blood trough concentrations (C ) and the tacrolimus concentration/weight-adjusted dose ratio on day 1 was evaluated in 67 liver-transplanted children: 33 boys and 34 girls, mean age 4.5 years.
Donor CYP3A5 genotype appears to be significantly associated with tacrolimus disposition on the first day after liver transplantation (P < 0.0002). Other physiological factors, such as recipient age and donor gender may also play a role and lead to significant differences in tacrolimus C and tacrolimus concentration/weight-adjusted dose ratio on day 1. However, according to the general linear model, only recipient age appears to be independently associated with tacrolimus disposition on the first day after liver transplantation (P < 0.03). Indeed, there was a faster tacrolimus metabolism in children under 6 years of age (P < 0.02).
Donor CYP3A5 genotype, recipient age and, to a lesser extent, donor gender appear to be associated with tacrolimus disposition on day 1 after transplant. This suggests that increasing the starting tacrolimus doses in paediatric patients under 6 years of age who receive a graft from a male extensive metabolizer may enhance the possibility of their tacrolimus levels reaching the therapeutic range sooner.
本研究旨在调查细胞色素P450(CYP)3A4/5基因型在小儿肝移植受者和供者中的影响,以及年龄和性别对移植后第一天他克莫司处置的作用。
在67例肝移植儿童中评估了小儿肝移植受者和供者的CYP3A4/5基因型对他克莫司血谷浓度(C)和移植后第1天他克莫司浓度/体重调整剂量比的作用:33例男孩和34例女孩,平均年龄4.5岁。
供者CYP3A5基因型似乎与肝移植后第一天他克莫司的处置显著相关(P<0.0002)。其他生理因素,如受者年龄和供者性别也可能起作用,并导致移植后第1天他克莫司C和他克莫司浓度/体重调整剂量比出现显著差异。然而,根据一般线性模型,只有受者年龄似乎与肝移植后第一天他克莫司的处置独立相关(P<0.03)。事实上,6岁以下儿童的他克莫司代谢更快(P<0.02)。
供者CYP3A5基因型、受者年龄以及在较小程度上供者性别似乎与移植后第1天他克莫司的处置相关。这表明,对于接受来自男性广泛代谢者移植物的6岁以下小儿患者,增加他克莫司起始剂量可能会提高其他克莫司水平更快达到治疗范围的可能性。